200 related articles for article (PubMed ID: 35363388)
1. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity.
Frejat FOA; Cao Y; Wang L; Zhai H; Abdelazeem AH; Gomaa HAM; Youssif BGM; Wu C
Arch Pharm (Weinheim); 2022 Jul; 355(7):e2100516. PubMed ID: 35363388
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
3. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study.
Ibrahim TS; Almalki AJ; Moustafa AH; Allam RM; Abuo-Rahma GEA; El Subbagh HI; Mohamed MFA
Bioorg Chem; 2021 Jun; 111():104885. PubMed ID: 33838559
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
5. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
7. New potent ciprofloxacin-uracil conjugates as DNA gyrase and topoisomerase IV inhibitors against methicillin-resistant Staphylococcus aureus.
Samir M; Ramadan M; Abdelrahman MH; Elbastawesy MAI; Halby HM; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Med Chem; 2022 Nov; 73():117004. PubMed ID: 36148773
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
10. A new exploration toward adamantane derivatives as potential anti-MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors.
Ragab A; Abusaif MS; Aboul-Magd DS; Wassel MMS; Elhagali GAM; Ammar YA
Drug Dev Res; 2022 Sep; 83(6):1305-1330. PubMed ID: 35716118
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors.
Mohammed HHH; Ali DME; Badr M; Habib AGK; Mahmoud AM; Farhan SM; Gany SSHAE; Mohamad SA; Hayallah AM; Abbas SH; Abuo-Rahma GEA
Mol Divers; 2023 Aug; 27(4):1751-1765. PubMed ID: 36152132
[TBL] [Abstract][Full Text] [Related]
12. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
[TBL] [Abstract][Full Text] [Related]
13. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
14. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
15. Structure based design and synthesis of 3-(7-nitro-3-oxo-3,4-dihydroquinoxalin-2-yl)propanehydrazide derivatives as novel bacterial DNA-gyrase inhibitors: In-vitro, In-vivo, In-silico and SAR studies.
Saleh MA; Elmaaty AA; El Saeed HS; Saleh MM; Salah M; Ezz Eldin RR
Bioorg Chem; 2022 Dec; 129():106186. PubMed ID: 36215786
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Evaluation of Novel Tyrosine-Based DNA Gyrase B Inhibitors.
Cotman AE; Trampuž M; Brvar M; Kikelj D; Ilaš J; Peterlin-Mašič L; Montalvão S; Tammela P; Frlan R
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28621824
[TBL] [Abstract][Full Text] [Related]
17. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Antibacterial Screening of Some Novel Heteroaryl-Based Ciprofloxacin Derivatives as DNA Gyrase and Topoisomerase IV Inhibitors.
Al-Wahaibi LH; Amer AA; Marzouk AA; Gomaa HAM; Youssif BGM; Abdelhamid AA
Pharmaceuticals (Basel); 2021 Apr; 14(5):. PubMed ID: 33922361
[TBL] [Abstract][Full Text] [Related]
19. Development and radiosterilization of new hydrazono-quinoline hybrids as DNA gyrase and topoisomerase IV inhibitors: Antimicrobial and hemolytic activities against uropathogenic isolates with molecular docking study.
Ammar YA; Micky JA; Aboul-Magd DS; Abd El-Hafez SMA; Hessein SA; Ali AM; Ragab A
Chem Biol Drug Des; 2023 Feb; 101(2):245-270. PubMed ID: 36305722
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]